Micro-X Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Micro-X wird ein Gewinn- und Umsatzwachstum von 68.7% bzw. 38.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 87.8% pro Jahr wachsen soll.

Wichtige Informationen

68.7%

Wachstumsrate der Gewinne

87.8%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.1%
Wachstumsrate der Einnahmen	38.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	31 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

CHIA:MX1 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2027	52	4	N/A	2	1
6/30/2026	37	-5	N/A	-6	1
6/30/2025	25	-7	N/A	0	1
6/30/2024	15	-10	-7	-6	N/A
3/31/2024	15	-12	-6	-6	N/A
12/31/2023	15	-15	-5	-5	N/A
9/30/2023	15	-13	-9	-8	N/A
6/30/2023	15	-11	-12	-11	N/A
3/31/2023	15	-11	-14	-13	N/A
12/31/2022	15	-12	-15	-14	N/A
9/30/2022	12	-15	-17	-16	N/A
6/30/2022	9	-17	-19	-18	N/A
3/31/2022	6	-18	-18	-16	N/A
12/31/2021	4	-19	-16	-15	N/A
9/30/2021	4	-17	-13	-12	N/A
6/30/2021	4	-15	-11	-10	N/A
3/31/2021	5	-13	-12	-11	N/A
12/31/2020	6	-11	-13	-12	N/A
9/30/2020	5	-10	-12	-11	N/A
6/30/2020	4	-10	-12	-9	N/A
3/31/2020	3	-9	-11	-8	N/A
12/31/2019	2	-8	-10	-7	N/A
9/30/2019	2	-9	-9	-7	N/A
6/30/2019	2	-10	-9	-7	N/A
3/31/2019	2	-14	-9	-8	N/A
12/31/2018	2	-18	-10	-9	N/A
9/30/2018	2	-17	-9	-8	N/A
6/30/2018	2	-17	-8	-8	N/A
3/31/2018	1	-14	N/A	-9	N/A
12/31/2017	1	-11	N/A	-11	N/A
9/30/2017	1	-12	N/A	-11	N/A
6/30/2017	1	-13	N/A	-11	N/A
3/31/2017	1	-13	N/A	-10	N/A
12/31/2016	1	-13	N/A	-9	N/A
9/30/2016	1	-12	N/A	-11	N/A
6/30/2016	1	-11	N/A	-13	N/A
3/31/2016	1	-12	N/A	-10	N/A
12/31/2015	0	-13	N/A	-8	N/A
9/30/2015	0	-11	N/A	-7	N/A
6/30/2015	0	-10	N/A	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MX1 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: MX1 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: MX1 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: MX1Die Einnahmen des Unternehmens (38.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (5.6% pro Jahr).

Hohe Wachstumseinnahmen: MX1Die Einnahmen des Unternehmens (38.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von MX1 in 3 Jahren voraussichtlich hoch sein wird

Micro-X Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast to breakeven in 2027

Forecast breakeven date pushed back to 2025

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Recent updates

Micro-X Limited, Annual General Meeting, Nov 12, 2024

Full year 2024 earnings released

Forecast to breakeven in 2027

Micro-X Limited has completed a Follow-on Equity Offering in the amount of AUD 3.9 million.

New minor risk - Shareholder dilution

Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.

Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 4 million.

Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.

Micro-X Reveals First Look At New Mobile Stroke Diagnosis Device

New minor risk - Profitability

Micro-X Limited, Annual General Meeting, Nov 16, 2023

Full year 2023 earnings released: AU$0.022 loss per share (vs AU$0.037 loss in FY 2022)

New minor risk - Financial data availability

Forecast breakeven date pushed back to 2025

First half 2023 earnings released: AU$0.008 loss per share (vs AU$0.019 loss in 1H 2022)

Less than half of directors are independent

Micro-X Limited announced that it has received AUD 7.454223 million in funding from Varex Imaging Corporation

Less than half of directors are independent

Less than half of directors are independent

Micro-X Limited, Annual General Meeting, Nov 14, 2022

Micro-X Limited Announces Resignation of Yasmin King as Director

Micro-X Limited announced that it expects to receive AUD 7.454223 million in funding from Varex Imaging Corporation

Micro-X Limited Launches Next Generation Micro-X Rover, the Rover Plus

Full year 2022 earnings released: AU$0.037 loss per share (vs AU$0.037 loss in FY 2021)

Micro-X Ltd Appoints Ilona Meyer to Its Board as A Non-Executive Director and Member of the Micro-X Audit & Risk Committee, Effective 7Th March 2022

Forecast to breakeven in 2024

Full year 2021 earnings released: AU$0.037 loss per share (vs AU$0.043 loss in FY 2020)

Forecast to breakeven in 2024

Micro-X Ltd Launches New Version of the Rover Mobile DR for Use in Small-Animal Veterinary Hospitals

Micro-X Limited Announces Rover FDA Approval Opens US Healthcare Market

First half 2021 earnings released: AU$0.013 loss per share (vs AU$0.025 loss in 1H 2020)

New 90-day high: AU$0.40

Micro-X Limited announced that it expects to receive AUD 30.5 million in funding

New 90-day high: AU$0.39

Micro-X Limited Signs $1.3 Million Rover Contract for Australian Defence Force

New 90-day high: AU$0.38

Micro-X Limited Announces Rejoining of Jim McDowell as Non-Executive Director from January 1, 2021

Micro-X Limited Amends Nano Distribution Agreement with Carestream Health Inc

Micro-X Ltd Announces Management Changes

New 90-day high: AU$0.26

Micro-X Limited Signs $1.4 Million Contract for Rover Launches Micro-X Second Product

New 90-day high: AU$0.21

Micro-X Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.043 loss per share

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken